• Target：
• RANKL

• Fields：
• >>Cytokine-cytokine receptor interaction;>>NF-kappa B signaling pathway;>>Osteoclast differentiation;>>Prolactin signaling pathway;>>Parathyroid hormone synthesis, secretion and action;>>Chemical carcinogenesis - receptor activation;>>Breast cancer;>>Rheumatoid arthritis

• Gene Name：
• TNFSF11

• Protein Name：
• Tumor necrosis factor ligand superfamily member 11

• Human Gene Id：
• 8600

• Human Swiss Prot No：
• O14788

• Mouse Gene Id：
• 21943

• Mouse Swiss Prot No：
• O35235

• Rat Gene Id：
• 117516

• Rat Swiss Prot No：
• Q9ESE2

• Immunogen：
• The antiserum was produced against synthesized peptide derived from the C-terminal region of human TNFSF11. AA range:268-317

• Specificity：
• RANKL Polyclonal Antibody detects endogenous levels of RANKL protein.

• Formulation：
• Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

• Source：
• Polyclonal, Rabbit,IgG

• Dilution：
• WB 1:500 - 1:2000. IHC: 1:100-300 ELISA: 1:20000. IF 1:100-300 Not yet tested in other applications.

• Purification：
• The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

• Concentration：
• 1 mg/ml

• Storage Stability：
• -15°C to -25°C/1 year(Do not lower than -25°C)

• Other Name：
• TNFSF11;OPGL;RANKL;TRANCE;Tumor necrosis factor ligand superfamily member 11;Osteoclast differentiation factor;ODF;Osteoprotegerin ligand;OPGLReceptor activator of nuclear factor kappa-B ligand;RANKL;TNF-related activation-induced cytokine;TRANCE;CD254

• Observed Band(KD)：
• 35kD

• Background：
• This gene encodes a member of the tumor necrosis factor (TNF) cytokine family which is a ligand for osteoprotegerin and functions as a key factor for osteoclast differentiation and activation. This protein was shown to be a dentritic cell survival factor and is involved in the regulation of T cell-dependent immune response. T cell activation was reported to induce expression of this gene and lead to an increase of osteoclastogenesis and bone loss. This protein was shown to activate antiapoptotic kinase AKT/PKB through a signaling complex involving SRC kinase and tumor necrosis factor receptor-associated factor (TRAF) 6, which indicated this protein may have a role in the regulation of cell apoptosis. Targeted disruption of the related gene in mice led to severe osteopetrosis and a lack of osteoclasts. The deficient mice exhibited defects in early differentiation of T and B ly

• Function：
• disease:Defects in TNFSF11 are the cause of osteopetrosis autosomal recessive type 2 (OPTB2) [MIM:259710]; also known as osteoclast-poor osteopetrosis. Osteopetrosis is a rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. The disorder occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. Autosomal recessive osteopetrosis is usually associated with normal or elevated amount of non-functional osteoclasts. OPTB2 is characterized by paucity of osteoclasts, suggesting a molecular defect in osteoclast development.,function:Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an

• Subcellular Location：
• [Isoform 1]: Cell membrane; Single-pass type II membrane protein.; [Isoform 3]: Cell membrane; Single-pass type II membrane protein.; [Isoform 2]: Cytoplasm .; [Tumor necrosis factor ligand superfamily member 11, soluble form]: Secreted .

• Expression：
• Highest in the peripheral lymph nodes, weak in spleen, peripheral blood Leukocytes, bone marrow, heart, placenta, skeletal muscle, stomach and thyroid.

NCX1 disturbs calcium homeostasis and promotes RANKL-induced osteoclast differentiation by regulating JNK/c-Fos/NFATc1 signaling pathway in multiple myeloma

Protective effects of apple polyphenols on bone loss in mice with high fat diet-induced obesity WB Mouse 1 : 1000 femurs/

HIF‐1α facilitates osteocyte‐mediated osteoclastogenesis by activating JAK2/STAT3 pathway in vitro. JOURNAL OF CELLULAR PHYSIOLOGY 2019 Apr 29 WB,IF Mouse 1:200,1:500 MLO-Y4 cell

Alleviative Effects of Exercise on Bone Remodeling in Fluorosis Mice. BIOLOGICAL TRACE ELEMENT RESEARCH Biol Trace Elem Res. 2022 Mar;200(3):1248-1261 IHC,WB Mouse 1 : 100，1:400 Femur tissue

• June 19-2018
• WESTERN IMMUNOBLOTTING PROTOCOL

• June 19-2018
• IMMUNOHISTOCHEMISTRY-PARAFFIN PROTOCOL

• June 19-2018
• IMMUNOFLUORESCENCE PROTOCOL

• September 08-2020
• FLOW-CYTOMEYRT-PROTOCOL

• May 20-2022
• Cell-Based ELISA│解您多样本WB检测之困扰

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-ACETYL-PROTEIN

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-PHOSPHO-PROTEIN

• July 13-2018
• CELL-BASED-COLORIMETRIC-ELISA-PROTOCOL-FOR-TOTAL-PROTEIN

• July 13-2018
• Antibody-FAQs